WEKO3
アイテム
{"_buckets": {"deposit": "6d7fe6a4-81a9-438b-8df0-d6b966d1d3eb"}, "_deposit": {"created_by": 2, "id": "6785", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "6785"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00006785", "sets": ["30"]}, "author_link": ["28449", "28448", "28454", "28447", "28455", "28456", "28452", "28451", "28453", "28457", "28450", "28458"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-04", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "298", "bibliographicPageStart": "291", "bibliographicVolumeNumber": "19", "bibliographic_titles": [{"bibliographic_title": "Journal of Infection and Chemotherapy"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Healthcare-associated pneumonia (HCAP) may have a more severe course than community-acquired pneumonia (CAP); hence, it is more likely to be caused by drug-resistant bacterial pathogens and anaerobes involved in aspiration pneumonia. We compared the efficacy and safety of initial empiric therapy with piperacillin/tazobactam (PIPC/TAZ, 13.5 g/day) with that of meropenem (MEPM, 1.5 g/day) as single broad-spectrum regimens with gram-negative and anaerobic coverage in patients with HCAP in Japan. The clinical cure rate was 75.9 % (22/29 cases) in the PIPC/TAZ group and 64.3 % (18/28 cases) in the MEPM group. The clinical efficacy rate was 87.9 % (29/33 cases) in the PIPC/TAZ group and 74.2 % (23/31 cases) in the MEPM group. The bacteriological eradication rate was 94.4 % (17/18) in the PIPC/TAZ group and 87.5 % (14/16) in the MEPM group. Adverse drug reactions were seen in 22.4 % (11/49 cases) of patients in the PIPC/TAZ group and 17.4 % (8/46 cases) of patients in the MEPM group. Although not statistically different, the PIPC/TAZ group had a slightly higher efficacy rate than the MEPM group. Both treatment regimens are tolerable and might be appropriate to use as initial empiric therapy for HCAP in Japan. To investigate the differences in efficacy profiles of those two regimens, a further confirmatory study with a larger cohort as determined by a power analysis is recommended.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Journal of Infection and Chemotherapy, 19(2), pp.291-298; 2013", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "日本化学療法学会・日本感染症学会"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1007/s10156-013-0552-6", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2013 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases."}, {"subitem_rights": "The final publication is available at www.springerlink.com"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341321X", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "14377780", "subitem_source_identifier_type": "ISSN"}]}, "item_2_text_62": {"attribute_name": "出版者別言語", "attribute_value_mlt": [{"subitem_text_value": "Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yamamoto, Yoshihiro"}], "nameIdentifiers": [{"nameIdentifier": "28447", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Izumikawa, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "28448", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morinaga, Yoshitomo"}], "nameIdentifiers": [{"nameIdentifier": "28449", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakamura, Shigeki"}], "nameIdentifiers": [{"nameIdentifier": "28450", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurihara, Shintaro"}], "nameIdentifiers": [{"nameIdentifier": "28451", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Imamura, Yoshifumi"}], "nameIdentifiers": [{"nameIdentifier": "28452", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Miyazaki, Taiga"}], "nameIdentifiers": [{"nameIdentifier": "28453", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsukamoto, Misuzu"}], "nameIdentifiers": [{"nameIdentifier": "28454", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kakeya, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "28455", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yanagihara, Katsunori"}], "nameIdentifiers": [{"nameIdentifier": "28456", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasuoka, Akira"}], "nameIdentifiers": [{"nameIdentifier": "28457", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "28458", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "JIC19_291.pdf", "filesize": [{"value": "331.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 331400.0, "url": {"label": "JIC19_291.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/6785/files/JIC19_291.pdf"}, "version_id": "38487e7f-7b64-40b3-a777-30f24d37d536"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Antimicrobials", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Healthcare-associated pneumonia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Meropenem", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Nursing and healthcare-associated pneumonia", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Piperacillin/tazobactam", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/33794", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-09-24"}, "publish_date": "2013-09-24", "publish_status": "0", "recid": "6785", "relation": {}, "relation_version_is_last": true, "title": ["Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan"], "weko_shared_id": -1}
Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan
http://hdl.handle.net/10069/33794
http://hdl.handle.net/10069/337946dffbdbc-e395-42d8-bf42-8a01b59b10b1
名前 / ファイル | ライセンス | アクション |
---|---|---|
JIC19_291.pdf (331.4 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-09-24 | |||||
タイトル | ||||||
タイトル | Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Antimicrobials | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Healthcare-associated pneumonia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Meropenem | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Nursing and healthcare-associated pneumonia | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Piperacillin/tazobactam | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Yamamoto, Yoshihiro
× Yamamoto, Yoshihiro× Izumikawa, Koichi× Morinaga, Yoshitomo× Nakamura, Shigeki× Kurihara, Shintaro× Imamura, Yoshifumi× Miyazaki, Taiga× Tsukamoto, Misuzu× Kakeya, Hiroshi× Yanagihara, Katsunori× Yasuoka, Akira× Kohno, Shigeru |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Healthcare-associated pneumonia (HCAP) may have a more severe course than community-acquired pneumonia (CAP); hence, it is more likely to be caused by drug-resistant bacterial pathogens and anaerobes involved in aspiration pneumonia. We compared the efficacy and safety of initial empiric therapy with piperacillin/tazobactam (PIPC/TAZ, 13.5 g/day) with that of meropenem (MEPM, 1.5 g/day) as single broad-spectrum regimens with gram-negative and anaerobic coverage in patients with HCAP in Japan. The clinical cure rate was 75.9 % (22/29 cases) in the PIPC/TAZ group and 64.3 % (18/28 cases) in the MEPM group. The clinical efficacy rate was 87.9 % (29/33 cases) in the PIPC/TAZ group and 74.2 % (23/31 cases) in the MEPM group. The bacteriological eradication rate was 94.4 % (17/18) in the PIPC/TAZ group and 87.5 % (14/16) in the MEPM group. Adverse drug reactions were seen in 22.4 % (11/49 cases) of patients in the PIPC/TAZ group and 17.4 % (8/46 cases) of patients in the MEPM group. Although not statistically different, the PIPC/TAZ group had a slightly higher efficacy rate than the MEPM group. Both treatment regimens are tolerable and might be appropriate to use as initial empiric therapy for HCAP in Japan. To investigate the differences in efficacy profiles of those two regimens, a further confirmatory study with a larger cohort as determined by a power analysis is recommended. | |||||
書誌情報 |
Journal of Infection and Chemotherapy 巻 19, 号 2, p. 291-298, 発行日 2013-04 |
|||||
出版者 | ||||||
出版者 | 日本化学療法学会・日本感染症学会 | |||||
出版者別言語 | ||||||
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases | ||||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1341321X | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 14377780 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1007/s10156-013-0552-6 | |||||
権利 | ||||||
権利情報 | © 2013 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. | |||||
権利 | ||||||
権利情報 | The final publication is available at www.springerlink.com | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal of Infection and Chemotherapy, 19(2), pp.291-298; 2013 |